Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 7/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | FADS1 | O60427 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.34 |
| ▸ | MERTK | Q12866 | 4/20 | 0.34 |
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955467 | 1.00 | AXL (0.37) | AXLMETFADS1ENPP2HRH4 | |
| Hydrochloric Acid SCHEMBL5128633 | 0.99 | AXL (0.36) | AXLMETFADS1ENPP2HRH4 | |
| Hydrochloric Acid SCHEMBL5128628 | 0.99 | AXL (0.36) | AXLMETFADS1ENPP2HRH4 | |
| SCHEMBL3955443 | 0.90 | AXL (0.37) | AXLMETFADS1TYRO3MERTK | |
| SCHEMBL3955446 | 0.90 | AXL (0.37) | AXLMETFADS1TYRO3MERTK | |
| Hydrochloric Acid SCHEMBL3963592 | 0.90 | AXL (0.37) | AXLMETFADS1TYRO3MERTK | |
| Hydrochloric Acid SCHEMBL3963588 | 0.90 | AXL (0.37) | AXLMETFADS1TYRO3MERTK | |
| SCHEMBL3957545 | 0.86 | MAPT (0.42) | AXLKHK | |
| SCHEMBL3961228 | 0.86 | MAPT (0.42) | AXLKHK | |
| SCHEMBL3964249 | 0.86 | MAPT (0.42) | AXLKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | claimed |
| EP-2079737-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-22 | — | — | EP | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | SCN1A, SCN3A, SCN1B | AXL 4584/4885MET 4091/4885FADS1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.